Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Thursday 04 May, 2006

XTL Biopharm Ltd

Initiation of Patient Dosing in XTL-2125 Clinic...

XTL Biopharmaceuticals Ltd. initiates patient dosing in Phase 1 clinical trial 
of XTL-2125, an oral, non-nucleoside polymerase inhibitor for the treatment of 
                                  hepatitis C                                  

    Study will assess safety and anti-viral activity of XTL-2125 in chronic    
                             hepatitis C patients                              

New York, NY, May 4, 2006 - XTL Biopharmaceuticals Ltd. ("XTLbio") (NASDAQ:
XTLB; LSE: XTL; TASE: XTL) today announced the initiation of patient dosing in
a Phase 1 clinical trial of XTL-2125 for the treatment of chronic hepatitis C.
The Phase 1 trial is a placebo controlled, randomized, dose escalating study,
which will evaluate the safety, tolerability and antiviral activity of single
and multiple doses of XTL-2125. The study will enroll 48 patients into 6
cohorts comprised of 8 patients each (of which 2 are placebo patients). Each
patient will receive a single dose, followed by a 14-day multi-dosing regimen
commencing one week after the single dose administration.

XTL-2125 is an oral non-nucleoside hepatitis C virus polymerase inhibitor. In
pre-clinical studies, XTL-2125 has demonstrated robust activity against the
hepatitis C virus in both cell-based and in-vivo systems. In addition, XTL-2125
has demonstrated a good safety profile in multiple animal species.

Ron Bentsur, XTLbio's Chief Executive Officer, commented: "With the
commencement of dosing in the XTL-2125 Phase 1 trial, XTLbio is in the unique
position of having 2 novel compounds - XTL-2125 and XTL-6865 - in clinical
trials in patients with chronic hepatitis C. We look forward to generating
antiviral activity data from both studies over the next 12 months." Mr. Bentsur
added, "The initiation of patient dosing in the XTL-2125 study on schedule
demonstrates our strong commitment to meeting the timelines that we have set
out for our programs."

Investor Relations Contact:

Ron Bentsur
Tel: +1-212-531-5971
[email protected]


XTL Biopharmaceuticals Ltd. ("XTLbio") is engaged in the acquisition,
development and commercialization of therapeutics for the treatment of
infectious diseases, with a focus on hepatitis C. XTLbio is developing XTL-2125
- a small molecule, non-nucleoside inhibitor of the hepatitis C virus
polymerase. XTL-2125 is currently in a Phase 1 clinical trial in chronic
hepatitis C patients. XTLbio is also developing XTL-6865 - a combination of two
monoclonal antibodies against the hepatitis C virus - presently in Phase 1
clinical trials in patients with chronic hepatitis C. XTLbio's hepatitis C
pipeline also includes several families of pre-clinical hepatitis C small
molecule inhibitors.  In addition, XTLbio has out-licensed to Cubist
Pharmaceuticals an antibody therapeutic against hepatitis B, HepeX-B, which has
recently completed a Phase 2b clinical study in hepatitis B liver transplant
patients. XTLbio is publicly traded on the NASDAQ, London, and Tel-Aviv Stock

Cautionary Statement

Some of the statements included in this press release, particularly those
anticipating future financial performance, clinical and business prospects for
our clinical compounds for hepatitis C, XTL-2125 and XTL-6865, growth and
operating strategies and similar matters, may be forward-looking statements
that involve a number of risks and uncertainties. For those statements, we
claim the protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995. Among the
factors that could cause our actual results to differ materially are the
following: our ability to successfully complete cost-effective clinical trials
for the drug candidates in our pipeline which would affect our ability to
continue to fund our operations with our available cash reserves, our ability
to meet anticipated development timelines for the drug candidates in our
pipeline due to recruitment, clinical trial results, manufacturing capabilities
or other factors; and other risk factors identified from time to time in our
reports filed with the Securities and Exchange Commission and the London Stock
Exchange. Any forward-looking statements set forth in this press release speak
only as of the date of this press release. We do not intend to update any of
these forward-looking statements to reflect events or circumstances that occur
after the date hereof. This press release and prior releases are available at The information in our website is not incorporated by
reference into this press release and is included as an inactive textual
reference only.


a d v e r t i s e m e n t